Telix to Present Phase III ProstACT GLOBAL Study (TLX591 Therapy) and Phase II STARBURST Study (TLX250-CDx Indication Expansion) at EAU

Melbourne (Australia) | 28 March 2024 Telix today announces presentations featuring the Company’s late-stage theranostic programs at the 39th Annual European Association of Urology Congress (EAU24), Europe’s largest urological event, being held in Paris (France) from 5-8 April 2024.  Dr David N. Cade, Telix Group Chief Medical Officer, said, “We are pleased to present an update on ProstACT GLOBAL, the first Phase III study to evaluate Telix’s lead investigational radio antibody-drug conjugate (rADC) therapy, TLX591,1 in patients with PSMA2-positive mCRPC3 progressing on first-line androgen receptor pathway inhibition.  “Additionally, we will present STARBURST, a Phase II study of the Company’s investigational PET/CT4 imaging agent TLX250-CDx,5 exploring carbonic anhydrase IX (CAIX) as a potential target across a broad range of cancer indications. Building on the success of our Phase III ZIRCON study in clear cell renal cell carcinoma (ccRCC)6, STARBURST is adding clinical insight, enabling Telix to assess the potential of CAIX as a biomarker as we continue to scout theranostic potential of the TLX250 platform beyond kidney cancer.  “We look forward to seeing you at our booth #F42 to discuss Telix’s extensive late-stage urologic pipeline, our associated medical devices, and opportunities for collaboration.”  EAU24 presentation details are listed below:  Session: EGPT 11 – Prostate Cancer Screening – Prime Time for Organized Screening Strategies?  Title: ProstACT GLOBAL: A phase III study best standard of care with and without 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug  Location: EGPT, Screen D, Trials in progress  Date and Time: Sunday 7 April, 2024 | 18:00 – 18:15 (CEST)  Presenter: E. Debret, Telix Pharmaceuticals  Abstract: P307  ClinicalTrials.gov ID: NCT04876651  Session: EGPT 11 – Prostate Cancer Screening – Prime Time for Organized Screening Strategies?  Title: 89Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX (STARBURST)  Location: EGPT, Screen F  Date and Time: Sunday 7 April, 2024 | 18:27 – 18:45 (CEST)  Presenter: S. Dalleau, Telix Pharmaceuticals  Abstract: P317  ClinicalTrials.gov ID: NCT05563272  177Lu rosopatamab tetraxetan. ↩︎ Prostate-specific membrane antigen. ↩︎ Metastatic castrate-resistant prostate cancer. ↩︎ Positron emission tomography/computed tomography. ↩︎ 89Zr-DFO-girentuximab. ↩︎ Telix ASX disclosures 7 November 2022. ↩︎

The release as fetched from its publisher. telixpharma.com ↗